Search research articles
Contact Us
Filters
Showing results (181-190 of 430) with videos related to
Page
of 43
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2001
Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer
C J Logothetis, K K Wu, L D Finn, et al.
Cancer Informatics
|
May 22, 2009
Merging microarray data, robust feature selection, and predicting prognosis in prostate cancer
Jing Wang, Kim Anh Do, Sijin Wen, et al.
Cancer Gene Therapy
|
July 27, 1999
Tumor-suppressive activity of CD66a in prostate cancer
W Luo, M Tapolsky, K Earley, et al.
Annals of Clinical and Laboratory Science
|
November 1, 1996
Serum calcitonin in small cell carcinoma of the prostate
S J Sim, A B Glassman, J Y Ro, et al.
Urologic Oncology
|
January 13, 2011
Evidence for the existence of an organ specific, androgen-independent pathway of progression in patients with metastatic prostate cancer
J T Hsieh, H C Wu, Y Wang, et al.
Cancer Discovery
|
July 2, 2013
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer
Christopher J Logothetis, Gary E Gallick, Sankar N Maity, et al.
The Journal of Urology
|
January 1, 1989
Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience
C J Logothetis, F H Dexeus, C Chong, et al.
Urology
|
July 1, 1991
Serum biomarkers in metastatic renal cell carcinoma
F H Dexeus, C J Logothetis, A Sella, et al.
Urology
|
February 1, 1989
Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome
B Têtu, J Y Ro, A G Ayala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2002
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma
Lance C Pagliaro, Randall E Millikan, Shi-Ming Tu, et al.
Page
of 43
Search research articles
Search
Showing results (181-190 of 430) with videos related to
Sort By:
Page
of 43
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2001
Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer
C J Logothetis, K K Wu, L D Finn, et al.
Cancer Informatics
|
May 22, 2009
Merging microarray data, robust feature selection, and predicting prognosis in prostate cancer
Jing Wang, Kim Anh Do, Sijin Wen, et al.
Cancer Gene Therapy
|
July 27, 1999
Tumor-suppressive activity of CD66a in prostate cancer
W Luo, M Tapolsky, K Earley, et al.
Annals of Clinical and Laboratory Science
|
November 1, 1996
Serum calcitonin in small cell carcinoma of the prostate
S J Sim, A B Glassman, J Y Ro, et al.
Urologic Oncology
|
January 13, 2011
Evidence for the existence of an organ specific, androgen-independent pathway of progression in patients with metastatic prostate cancer
J T Hsieh, H C Wu, Y Wang, et al.
Cancer Discovery
|
July 2, 2013
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer
Christopher J Logothetis, Gary E Gallick, Sankar N Maity, et al.
The Journal of Urology
|
January 1, 1989
Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience
C J Logothetis, F H Dexeus, C Chong, et al.
Urology
|
July 1, 1991
Serum biomarkers in metastatic renal cell carcinoma
F H Dexeus, C J Logothetis, A Sella, et al.
Urology
|
February 1, 1989
Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome
B Têtu, J Y Ro, A G Ayala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2002
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma
Lance C Pagliaro, Randall E Millikan, Shi-Ming Tu, et al.
Page
of 43